Compounds > ecteinascidin 743
Page last updated: 2024-09-02

ecteinascidin 743 and Adenocarcinoma, Clear Cell

ecteinascidin 743 has been researched along with Adenocarcinoma, Clear Cell in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T1
Hayashi, M; Hisamatsu, T; Kawase, C; Kimura, T; Kurachi, H; Mabuchi, S; Mimura, K; Sawada, K; Takahashi, K; Takahashi, T1
Ikeda, Y; Kikuchi, Y; Kita, T; Kudoh, K; Sasaki, N; Takano, M1

Other Studies

3 other study(ies) available for ecteinascidin 743 and Adenocarcinoma, Clear Cell

ArticleYear
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:5

    Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured

2014
The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13

    Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dioxoles; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin; Xenograft Model Antitumor Assays

2011
Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.
    The journal of obstetrics and gynaecology research, 2013, Volume: 39, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dioxoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Tetrahydroisoquinolines; Trabectedin

2013